High-throughput screening for mTORC1/mTORC2 kinase inhibitors using a chemiluminescence-based ELISA assay

Assay and Drug Development Technologies

Volumn 7, Issue 5, 2009, Pages 471-478

  Bhagwat, Shripad V ^a   Kahler, Jennifer ^a   Yao, Yan ^a   Maresca, Paul ^a   Brooks, Maureen ^a   Crew, Andy ^a   Boisclair, Michael ^a   Pachter, Jonathan A ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BIOASSAY; CATALYSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PERFORMANCE MEASUREMENT SYSTEM; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE TRIPHOSPHATE; CHROMONES; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; INDICATORS AND REAGENTS; LUMINESCENCE; MORPHOLINES; PROTEIN KINASE INHIBITORS; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 70450247170     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2008.0183     Document Type: Article

References (13)

1. Guertin DA Sabatini DM: Defi ning the role of mTOR in cancer. Cell 2007; 12:9-22.
2. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95:1432-1437.
3. Gingras A-C, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, et al.: Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001;15:2852-2864.
4. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 2005;307:1098-1101.
5. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al.: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin sensitive. Nat Cell Biol 2004;6:1122-1128.
6. Tsang CK, Haiyan Q, Liu LF, Zheng XFT: Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-124.
7. Inoki K, Corradetti MN, Guan K-L: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19-24.
8. Chiang GG, Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-442.
9. Vignot S, Faivre S, Aguirre D, Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537.
10. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al.: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-defi cient glioblastoma. PLOS Med 2008;5:0139-0151.
11. Toral-Barza L, Zhang W-G, Lamison C, LaRocque J, Gibbons J, Yu K: Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specifi city, and enzyme inhibition as studied by a high capacity assay. Biochem Biophys Res Commun 2005;332:304-310.
12. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G: Mammalian TOR: a homeostatic ATP sensor. Science 2001;294:1102-1105.
13. Edelman AM, Blumenthal DK, Krebs EG: Protein serine/threonine kinases. Annu Rev Biochem 1987;56:567-613.